Literature DB >> 1824624

Elevated pulmonary artery pressure. An independent predictor of mortality.

R Cooper1, J Ghali, B E Simmons, A Castaner.   

Abstract

Analyses in this study were based on hemodynamic and angiographic data obtained in a cohort of 1,371 predominantly black patients during right and left heart catheterization. All patients were followed up prospectively for a mean of 117 weeks, and 103 fatal events were recorded. In Cox survival analysis, three variables were found to be independently related to survival: pulmonary artery mean pressure (PAMP), number of stenosed vessels, and left ventricular (LV) ejection fraction (p less than 0.01); in multivariate stepwise analysis, PAMP entered the model first with the largest chi 2 value of the three prognostic variables (chi 2 = 33.4; p less than 0.0001). The PAMP was 32 percent higher in decedents compared with survivors (25 + 11 mm Hg vs 19 + 8 mm Hg, p less than 0.01 [mean, SD]) and a 10 mm Hg increase in PAMP was associated with a more than fourfold increase in the relative risk of dying; this finding was independent of pulmonary vascular resistance and therefore could not be attributed to primary pulmonary vascular or parenchymal disease. In both the subgroup of 1,118 patients with a normal LV ejection fraction (greater than 50 percent) and the 253 patients with a reduced ejection fraction (less than 50 percent), PAMP emerged as an independent predictor of mortality (p less than 0.0001 and 0.01, respectively), and is therefore a marker of cardiac disease beyond impairment of systolic contractile function. Among patients without obstructive coronary artery disease, PAMP alone provided prognostic information in the multivariate survival analysis.

Entities:  

Mesh:

Year:  1991        PMID: 1824624     DOI: 10.1378/chest.99.1.112

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  17 in total

Review 1.  Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension.

Authors:  P Egermayer; G I Town; A J Peacock
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

2.  Therapeutic effect of low-dose imatinib on pulmonary arterial hypertension in dogs.

Authors:  Shinji Arita; Noboru Arita; Yoshiaki Hikasa
Journal:  Can Vet J       Date:  2013-03       Impact factor: 1.008

Review 3.  Exercise echocardiography for structural heart disease.

Authors:  Masaki Izumo; Yoshihiro J Akashi
Journal:  J Echocardiogr       Date:  2016-01-13

Review 4.  Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment.

Authors:  J L Wright; R D Levy; A Churg
Journal:  Thorax       Date:  2005-07       Impact factor: 9.139

5.  Vasodilators in pulmonary hypertension.

Authors:  A Peacock
Journal:  Thorax       Date:  1993-12       Impact factor: 9.139

6.  Echocardiographic evidence of pulmonary hypertension is associated with increased 1-year mortality in patients admitted with chronic obstructive pulmonary disease.

Authors:  Andrew C Stone; Jason T Machan; Jeffery Mazer; Brian Casserly; James R Klinger
Journal:  Lung       Date:  2011-05-10       Impact factor: 2.584

Review 7.  Exercise Testing and Stress Imaging in Aortic Valve Disease.

Authors:  Luc A Pierard; Raluca Dulgheru
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-07

Review 8.  Cardiac disease in chronic obstructive pulmonary disease.

Authors:  Jeremy A Falk; Steven Kadiev; Gerard J Criner; Steven M Scharf; Omar A Minai; Philip Diaz
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

9.  JNK2 up-regulates hypoxia-inducible factors and contributes to hypoxia-induced erythropoiesis and pulmonary hypertension.

Authors:  Marc A Sala; Cong Chen; Qiao Zhang; Hanh Chi Do-Umehara; Wenjiao Wu; Alexander V Misharin; Gregory B Waypa; Deyu Fang; G R Scott Budinger; Shuwen Liu; Navdeep S Chandel; Paul T Schumacker; Jacob I Sznajder; Jing Liu
Journal:  J Biol Chem       Date:  2017-11-08       Impact factor: 5.157

10.  Tissue factor pathway inhibitor overexpression inhibits hypoxia-induced pulmonary hypertension.

Authors:  Thomas A White; Tyra A Witt; Shuchong Pan; Cheryl S Mueske; Laurel S Kleppe; Eric W Holroyd; Hunter C Champion; Robert D Simari
Journal:  Am J Respir Cell Mol Biol       Date:  2009-07-31       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.